Advertisement

Bronchospasmolytika und Antiasthmatika

  • B. Lemmer

Zusammenfassung

Bronchospasmolytika werden zur Behandlung des Asthma bronchiale und der chronisch-obstruktiven Bronchitis (COPD) eingesetzt. Bei beiden Erkrankungen ist es das Ziel, die reversible Bronchialobstruktion zu beseitigen und die therapeutisch kaum noch zu beeinflussenden Zustände der Ateminsuffizienz und des Cor pulmonale so weit wie möglich zu bessern.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Allen D. B., Mullen M., Mullen B. A. (1994): A meta-analysis of the effect of oral and inhaled corticosteroids on growth. J. Allergy Clin. Immunol. 93: 967–976.PubMedCrossRefGoogle Scholar
  2. Arzneimittelkommission der deutschen Ärzteschaft (1997): Arzneiverordnungen. 18. Aufl., Deutscher Ärzte-Verlag, Köln, S. 484–495.Google Scholar
  3. Barnes P. J. (1995): Beta-adrenergic receptors and their regulation. Am. J. Respir. Crit. Care Med. 152: 838–860.PubMedGoogle Scholar
  4. Barnes P. J., Pauwels R. A. (1994): Theophylline in the management of asthma: time for reappraisal? Eur. Respir. J. 7: 579–591.PubMedCrossRefGoogle Scholar
  5. Barnes P. J., Holgate S. T., Laitinen L. A., Pauwels R. (1995): Asthma mechanisms, determinants of severity and treatment: the role of nedocromil sodium. Clin. Exp. Allergy 25: 771–787.PubMedCrossRefGoogle Scholar
  6. Bundesgesundheitsamt (1988): Aufbereitungsmonographie zu Cromoglicinsäure. Bundesanzeiger 40 vom 11.7.1998, S. 7-9.Google Scholar
  7. Cumming R. G., Mitchell P., Leeder S. R. (1997): Use of inhaled corticosteroids and the risk of cataracts. New Engl. J. Med. 337: 8–14.PubMedCrossRefGoogle Scholar
  8. Easton P. A., Jadue C., Dhingra S., Anthonisen N. R. (1986): A comparison of the bronchodilating effects of a beta-2 adrenergic agent (albuterol) and an anticho-linergic agent (ipratropium bromide), given by aerosol alone or in sequence. N. Engl. J. Med. 315: 735–739.PubMedCrossRefGoogle Scholar
  9. GINA — Global initiative for Asthma (1995): Global strategy for asthma management and prevention NHLI/WHO workshop report. National Heart, Lung, and Blood Institute, National Institutes of Health, Publication No 95-3569.Google Scholar
  10. Grahnén A., Eckernas S. A., Brundin R. M., Ling-Andersson A. (1994): An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers. Br. J. Clin. Pharmacol. 38: 521–525.PubMedCrossRefGoogle Scholar
  11. Gross N. J. (1988): Ipratropium bromide. N. Engl. J. Med. 319: 486–494.PubMedCrossRefGoogle Scholar
  12. Hanania N. A., Chapman K. R., Sturtridge W. C., Szalai J. P., Kesten S. (1995): Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids. J. Allergy Clin. Immunol. 96: 571–579.PubMedCrossRefGoogle Scholar
  13. Lemmer B. (1990): Chronopharmakologische Aspekte der Theophyllintherapie. In: Blume H. (Hrsg.): Bioäquivalenz retardierter Theophyllin-Fertigarzneimittel. Govi, Frankfurt, S. 75–82.Google Scholar
  14. McCowan C., Neville R. G., Thomas G.E., Crombie I. K., Clark R. A. et al. (1998): Effect of asthma and its treatment on growth: four year follow up of cohort of children from general practices in Tayside, Scotland. Brit. Med. J. 316: 668–672.Google Scholar
  15. National Heart, Lung, and Blood Institute (1992): International Consensus Report on Diagnosis and Management of Asthma. National Institutes of Health pub. no. 92-3642.Google Scholar
  16. National Heart, Lung, and Blood Institute and World Health Organization (1995): Global Initiative for Asthma [GINA]. National Institutes of Health, pub. no. 95-3659.Google Scholar
  17. National Heart, Lung, and Blood Institute (1997): Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma [EPR-2]. National Institutes of Health, pub. no. 97-4051.Google Scholar
  18. Palm D., Lemmer B. (1997): Erkrankungen der Atemwege. In: Fülgraff G., Palm D. (Hrsg.): Pharmakotherapie — Klinische Pharmakologie, 10. Aufl., Fischer Verlag, Stuttgart Jena Lübeck Ulm, S. 320–335.Google Scholar
  19. Serafin W. E. (1996): Drugs used in the treatment of asthma. In: Hardman J.H., Limbird L.E., Molinoff P.B., Ruddon R.W., Goodman Gilman A. (eds.): Goodman & Gilman The Pharmacological Basis of Therapeutics, 9th ed. McGraw Hill, New York, pp. 659–682.Google Scholar
  20. Schmidt H. (1994): Retardtheophyllin ist nicht gleich Retardtheophyllin. Atem-wegs-Lungenkr. 20: 223–231.Google Scholar
  21. Schultze-Werninghaus G. (1998): Medikamentöse Asthmatherapie: Brauchen wir einen neuen Stufenplan? Allergo. J. 7: 99–106.Google Scholar
  22. Sears M. R., Rea H. H., Fenwick J., Gillies A. J. D., Holst P. E. et al. (1987): 75 Deaths in asthmatics prescibed home nebulisers. Brit. Med. J. 294: 477–480.CrossRefGoogle Scholar
  23. Smolensky M. H., D’Alonso G. E. (1997): Progress in the chronotherapy of nocturnal asthma. In: Redfern P., Lemmer B. (eds.): Physiology and Pharmacology of Biological Rhythms. Handbook of Experimental Pharmacology, Vol. 125, Springer, Berlin, Heidelberg, New York, pp. 205–249.Google Scholar
  24. Weinberger M., Hendeles L. (1996): Theophylline in asthma. N. Engl. J. Med. 334: 1380–1388.PubMedCrossRefGoogle Scholar
  25. Wettengel R., Berdel D., Cegla U., Fabel H., Geisler L. et al. (1994): Empfehlungen der Deutschen Atemwegsliga zum Asthmamanagement bei Erwachsenen und bei Kindern. Med. Klin. 89: 57–67.Google Scholar
  26. Williams M. H. (1989): Increasing severity of asthma from 1960 to 1987. N. Engl. J. Med. 320: 1015–1020.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1999

Authors and Affiliations

  • B. Lemmer

There are no affiliations available

Personalised recommendations